Videos

GALAXY: Disease-Free Survival by Stage and ctDNA Status

Mark Lewis, MD, provides a historical perspective of circulating tumor DNA and discusses previous trials on ctDNA analysis in patients with CRC.

Stacey A. Cohen, MD;Mark Lewis, MD

Transplant-Ineligible Multiple Myeloma: The MAIA Trial

Stacy A. Cohen, MD, and Mark Lewis, MD, comment on disease-free survival rates by ctDNA status in patients enrolled in the GALAXY study.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Case Presentation: An 82-Year-Old Woman with Transplant-Ineligible Multiple Myeloma

An overview of the study design, efficacy, and safety findings of the MAIA trial.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Sequencing Strategies for Renal Cell Carcinoma Treatment Regimens

Dr Nisha Joseph presents the case of a woman with transplant-ineligible multiple myeloma and discusses considerations when choosing frontline treatment regimens.

Thomas E. Hutson, DO, PharmD;Scott S. Tykodi, MD, PhD

Side Effects of IO/TKI Treatment Regimens for Renal Cell Carcinoma

A look at how to best sequence therapies for renal cell carcinoma from the front-line setting on.

Thomas E. Hutson, DO, PharmD

Subcutaneous Treatment of Early-Stage HER2+ Breast Cancer During the COVID-19 Pandemic

Thought leaders explain how they dose IO/TKI treatment regimens to better manage side effects in patients with renal cell carcinoma.

Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injections for Early-Stage HER2+ Breast Cancer

Sarah M. Tolaney, MD, MPH, describes her usage of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injections in her clinical practice during the COVID-19 pandemic for patients with HER2+ breast cancer.

Strategies for Prevention and Management of Adverse Events

An expert oncologist explains the combination subcutaneous injection therapy of pertuzumab, trastuzumab, and hyaluronidase-zzxf for patients with early-stage HER2+ breast cancer.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

Balancing Treatment Efficacy with Toxicity in Metastatic RCC

Chung-Han Lee, MD, PhD, provides a commentary on strategies for preventing and managing treatment-related adverse events in metastatic RCC.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

Uday R. Popat, MD, Discusses Rationale for Post-Transplant Cyclophosphamide as GVHD Prophylaxis in AML/MDS

David Aggen, MD, PhD, describes the challenges of balancing treatment efficacy versus toxicity and tolerability in patients with kidney cancer.

Uday R. Popat, MD

Alina Markova, MD, on Key Findings With Topical Ruxolitinib in Cutaneous Chronic GVHD

Uday R. Popat, MD, spoke about the decision to use post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease.

Alina Markova, MD

May 10th 2022

Alina Markova, MD, highlights important findings from a study assessing topical ruxolitinib INCB018424 phosphate 1.5% cream as a treatment for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Frontline Quadruplet Therapy in NDMM: GMMG-HD7

Shaji Kumar, MD, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic;David Dingli, MD, PhD;Prashant Kapoor, MD

May 10th 2022

Shared insight on the GMMG-HD7 study, which utilized a frontline isatuximab-containing quadruplet regimen in patients with newly diagnosed multiple myeloma.

Frontline Quadruplet Therapy in NDMM: GRIFFIN and MASTER Studies

Shaji Kumar, MD, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic;David Dingli, MD, PhD;Prashant Kapoor, MD

May 10th 2022

Expert perspectives on frontline daratumumab-containing quadruplet regimens in the context of recent clinical trials in newly diagnosed multiple myeloma.

Leptomeningeal Metastases in HER2+ Breast Cancer

Sara A. Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases

A neuro-oncologist explains the prevalence of leptomeningeal metastases in HER2+ breast cancer and her preferred method of treatment.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

Maintenance Therapy Duration and Considerations for Treatment Interruption

Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression

Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Maintenance Therapy Strategies for Transplant Eligible Multiple Myeloma

Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Matthew Krebs, MB, PhD, Reviews the Next Steps for Subcutaneous Amivantamab in Solid Tumors

Drs Ajay Nooka and Jonathan Kaufman discuss maintenance and consolidation treatment strategies for transplant eligible multiple myeloma.

Matthew Krebs, MB, PhD

Treatment Approaches for Patients with Newly Diagnosed Multiple Myeloma

Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Advice for Community Oncologists Treating Renal Cell Carcinoma

Experts discuss how they select a treatment regimen for a newly diagnosed multiple myeloma patient, and how they measure a successful treatment response.

Thomas E. Hutson, DO, PharmD;Scott S. Tykodi, MD, PhD

Peter Humphrey, MD, PhD, Discusses Current Role of Pathology in RCC

Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.

Peter Humphrey MD, PhD

Nicolas Girard, MD, on the Safety Profile of Nivolumab Plus Chemotherapy in Resectable NSCLC

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.

Nicolas Girard, MD

May 7th 2022

Nicolas Girard, MD, speaks with CancerNetwork® about the updated safety findings of nivolumab and chemotherapy in resectable non–small cell lung cancer.

David M. O’Malley, MD, Reviews the Benefit of Pembrolizumab for Endometrial Cancer

David O'Malley, MD, The Ohio State University Comprehensive Cancer Center

Frontline Treatment Options for Early-Stage HER2+ Breast Cancer

David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.

Goals of Care for Patients with Early-Stage versus Advanced or Metastatic HER2+ Breast Cancer

Sarah M. Tolaney, MD, MPH, reviews the treatment options for patients with early-stage HER2+ breast cancer in the frontline setting.

Use of Inotuzumab for ALL in the Frontline Setting

Sarah M. Tolaney, MD, MPH, provides an overview of how goals of care and prognosis differ between patients with early-stage HER2+ breast cancer and advanced or metastatic HER2+ breast cancer.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD

Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks

Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Varun Narendra, MD;Xiaoli Mi, MD;Meghan Thompson, MD